Resmed Inc (RMD) Dividends

For an income-focused value investor, ResMed's dividend is sustainable and backed by strong financial quality. The company's free cash flow yield of 5.0% and its low payout ratio—estimated below 40% using the provided EPS of $9.51 and dividend yield of 0.93%—indicate ample coverage. This aligns with the Quality Indicators in the investment framework, which favour companies with strong FCF generation and a solid balance sheet. ResMed's debt-to-equity ratio of 0.14 is exceptionally low, far below the framework's favourable threshold of Debt/EBITDA < 1.0x, providing significant financial flexibility. The dividend has a history of growth, having increased for over a decade, demonstrating management's commitment to returning capital while reinvesting for expansion. While the yield of 0.93% is below the sector average for healthcare equipment, which often ranges between 1-2%, this is typical for a company with ResMed's growth profile and high return on equity of 24.9%. The primary appeal is the combination of dividend growth, safety from a strong balance sheet, and the potential for capital appreciation, rather than high current income. The sustainable payout and consistent growth make the dividend profile favourable, though the modest absolute yield may not satisfy investors seeking immediate high income. Analysis based on data as of 2024-05-15.